Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Methylbenactyzium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 11/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 10/20 | 1.00 |
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 1.00 |
| ▸ | CHRM4 known ✓ | P08173 | 6/20 | 1.00 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.53 |
| ▸ | SCN1A | P35498 | 2/20 | 0.67 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.67 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylbenactyzium SCHEMBL669744 | 0.99 | CHRM1 (0.97) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Methylbenactyzium SCHEMBL8446490 | 0.97 | CHRM1 (0.95) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Methylbenactyzium SCHEMBL8816404 | 0.97 | CHRM1 (0.94) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Oxitefonium SCHEMBL2733669 | 0.87 | CHRM1 (0.76) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Lachesine SCHEMBL1946024 | 0.86 | CHRM1 (0.75) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Oxitefonium SCHEMBL29388802 | 0.85 | CHRM1 (0.73) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Metocinium SCHEMBL2108327 | 0.85 | CHRM2 (0.74) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Lachesine SCHEMBL3638169 | 0.84 | CHRM1 (0.73) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Metocinium SCHEMBL2732726 | 0.84 | CHRM2 (0.72) | CHRM1CHRM2CHRM3CHRM4SCN1A | |
| Bromide SCHEMBL31691733 | 0.80 | CHRM2 (0.67) | CHRM1CHRM2CHRM3CHRM4SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114030640-B | Method for evaluating the light environment of an aircraft cockpit | 中国航空无线电电子研究所 | 2023-10-27 | — | — | CN | claimed |
| CN-107913368-A | A kind of combination of Chinese tradiational and Western medicine medicine and preparation method for being used to treat biliary dyskinesia syndrome | 王晓艳 | 2018-04-17 | — | — | CN | claimed |
| CN-107913400-A | A kind of Chinese and western medicinal composition and preparation method for treating acute peritonitis | 周雷 | 2018-04-17 | — | — | CN | claimed |
| CN-104881855-A | Multi-focus image fusion method using morphology and free boundary condition active contour model | UNIV BEIHANG | 2015-09-02 | — | — | CN | claimed |
| CN-103400554-B | Testing method for light spread function template of LED zone backlight | UNIV HEFEI TECHNOLOGY | 2015-07-08 | — | — | CN | claimed |
| CN-104167013-A | Volume rendering method for highlighting target area in volume data | UNIV TSINGHUA | 2014-11-26 | — | — | CN | claimed |
| CN-103632136-A | Method and device for locating human eyes | BEIJING TECHSHINO TECHNOLOGY CO LTD | 2014-03-12 | — | — | CN | claimed |
| CN-102077925-B | Preparation for promoting synthesis and dendritic dispersion of skin melanin of fishes | GUANGDONG INST MICROBIOLOGY | 2012-09-05 | — | — | CN | claimed |
| CN-102077925-A | Preparation for promoting synthesis and dendritic dispersion of skin melanin of fishes | GUANGDONG INST MICROBIOLOGY | 2011-06-01 | — | — | CN | claimed |
| EP-1364659-B1 | REMEDIES FOR URINARY DISEASES COMPRISING LPA RECEPTOR CONTROLLING AGENTS | ONO PHARMACEUTICAL CO (JP) | 2009-11-11 | — | — | EP | claimed |
| US-7288558-B2 | Pharmaceutical composition for treatment for urinary diseases comprising LPA receptor regulator | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-30 | — | — | US | claimed |
| CN-1520818-A | Cholinesterase inhibitor pharmaceutical composition for senile dementia | ɽ����Ҷ��Ȼҩ���о���������˾ | 2004-08-18 | — | — | CN | claimed |
| US-20040067908-A1 | Remedies for urinary diseases comprising lpa receptor controlling agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-08 | — | — | US | claimed |
| EP-1364659-A1 | REMEDIES FOR URINARY DISEASES COMPRISING LPA RECEPTOR CONTROLLING AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-26 | — | — | EP | claimed |
| EP-0974361-A1 | METHOD OF USING ANTACID AGENT AND PHARMACEUTICAL PREPARATION CONTAINING ANTACID AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-01-26 | — | — | EP | claimed |
| CN-1183044-A | preparation composition containing sucralfate | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-05-27 | — | — | CN | claimed |
| EP-0823255-A1 | PHARMACEUTICAL COMPOSITION CONTAINING SUCRALFATE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1998-02-11 | — | — | EP | claimed |
| JP-8259466-A | — | — | None | — | — | JP | disclosed |
| EP-0452179-A2 | Polymer-combined drug for gastric treatment and a method for producing the drug | NIPPON OIL AND FATS COMPANY, LIMITED (JP) | 1991-10-16 | — | — | EP | disclosed |
| US-4567027-A | PRECIPITATION WITH ALUMINUM AND PHOSPHATE IONS | METALLURGIE HOBOKEN-OVERPELT (BE) | 1986-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067908-A1 | Remedies for urinary diseases comprising lpa receptor controlling agents | LPAR1, LPAR2, LPAR6 | CHRM1 1072/4885CHRM2 547/4885CHRM3 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.